Across 58 randomized controlled trials enrolling 24,214 non-diabetic adults with overweight or obesity, retatrutide — a triple GIP/GLP-1/glucagon receptor co-agonist — produced the greatest placebo-adjusted body weight reduction at -22.10%, edging tirzepatide (-19.28%) and the cagrilintide-semaglutide combination CagriSema (-17.32%). Conventional GLP-1 receptor agonists like liraglutide and older semaglutide formulations lagged substantially. Similar hierarchies held for waist circumference and lipid improvements. On tolerability, danuglipron and retatrutide showed higher discontinuation rates, while mazdutide appeared comparatively well-tolerated.
This network meta-analysis crystallizes what individual trials have hinted: the obesity pharmacotherapy field has undergone a genuine generational leap. Dual and triple receptor co-agonists are not incremental improvements — they are approaching the weight-loss magnitude historically achievable only through bariatric surgery. That retatrutide's 22% reduction exceeds even tirzepatide's robust 19% positions triple agonism as the current ceiling. For clinicians and patients, this ranking matters practically: drug choice increasingly involves trading maximal efficacy against tolerability profiles rather than simply asking whether a drug works. Limitations are real — network meta-analysis inherits heterogeneity across trials with differing durations, doses, and endpoints, and confidence intervals overlap for several pairwise comparisons. Evidence certainty was rated low for several safety outcomes. Crucially, long-term cardiovascular outcome data for most next-generation agents remain absent, and retatrutide has not yet received regulatory approval. This analysis is confirmatory of emerging trial data but provides the most comprehensive comparative ranking to date.